Answers are grounded in this paper and cite their sources.
The assessment of infection and sepsis remains challenging because microbiological methods are time-consuming and host-response biomarkers are not sufficiently specific across clinical settings. With its turnaround time, low sample volume, portability and ability to use whole blood, serum and plasma, lateral flow immunoassay (LFIA) provides a viable approach for decentralized measurement. This review examines LFIA platforms for procalcitonin, C-reactive protein, serum amyloid A, interleukin-6, pathogen antigens and multiplex panels. Special focus is placed on colorimetric, time-resolved fluorescence, quantum-dot, chemiluminescent, Raman, electrochemical, and smartphone-based readouts. The performance characteristics are evaluated with respect to analytical parameters, including detection and quantification limits, precision, calibration, and agreement with reference methods. The limitations due to hematocrit, viscosity, anticoagulants, hemolysis, and incomplete plasma separation are considered. There are platforms that demonstrate analytical sensitivity and show agreement with immunoassay platforms, but studies rely on spiked samples, single-centre cohorts, or nontransferable cutoff values. While multiplex formats may enhance biomarker discrimination, they do not resolve differences in concentration ranges or calibration complexity. Clinical translation is dependent on validation using native whole-blood samples, readouts, lot-to-lot quality control, decision thresholds, prospective studies in multiple centers and evidence that LFIA-based testing enhances antimicrobial stewardship and patient care across intensive-care settings.
No takes yet. Share an insight, caveat, or question.
Thapa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: